These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1176 related articles for article (PubMed ID: 9788453)

  • 1. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.
    Hacke W; Kaste M; Fieschi C; von Kummer R; Davalos A; Meier D; Larrue V; Bluhmki E; Davis S; Donnan G; Schneider D; Diez-Tejedor E; Trouillas P
    Lancet; 1998 Oct; 352(9136):1245-51. PubMed ID: 9788453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
    Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
    Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
    Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW
    Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
    Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
    Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
    Gusev EI; Martynov MY; Nikonov AA; Shamalov NA; Semenov MP; Gerasimets EA; Yarovaya EB; Semenov AM; Archakov AI; Markin SS;
    Lancet Neurol; 2021 Sep; 20(9):721-728. PubMed ID: 34418399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
    Campbell BCV; Ma H; Ringleb PA; Parsons MW; Churilov L; Bendszus M; Levi CR; Hsu C; Kleinig TJ; Fatar M; Leys D; Molina C; Wijeratne T; Curtze S; Dewey HM; Barber PA; Butcher KS; De Silva DA; Bladin CF; Yassi N; Pfaff JAR; Sharma G; Bivard A; Desmond PM; Schwab S; Schellinger PD; Yan B; Mitchell PJ; Serena J; Toni D; Thijs V; Hacke W; Davis SM; Donnan GA;
    Lancet; 2019 Jul; 394(10193):139-147. PubMed ID: 31128925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial.
    Alexandrov AV; Köhrmann M; Soinne L; Tsivgoulis G; Barreto AD; Demchuk AM; Sharma VK; Mikulik R; Muir KW; Brandt G; Alleman J; Grotta JC; Levi CR; Molina CA; Saqqur M; Mavridis D; Psaltopoulou T; Vosko M; Fiebach JB; Mandava P; Kent TA; Alexandrov AW; Schellinger PD;
    Lancet Neurol; 2019 Apr; 18(4):338-347. PubMed ID: 30878103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
    Logallo N; Novotny V; Assmus J; Kvistad CE; Alteheld L; Rønning OM; Thommessen B; Amthor KF; Ihle-Hansen H; Kurz M; Tobro H; Kaur K; Stankiewicz M; Carlsson M; Morsund Å; Idicula T; Aamodt AH; Lund C; Næss H; Waje-Andreassen U; Thomassen L
    Lancet Neurol; 2017 Oct; 16(10):781-788. PubMed ID: 28780236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset.
    Thomalla G; Simonsen CZ; Boutitie F; Andersen G; Berthezene Y; Cheng B; Cheripelli B; Cho TH; Fazekas F; Fiehler J; Ford I; Galinovic I; Gellissen S; Golsari A; Gregori J; Günther M; Guibernau J; Häusler KG; Hennerici M; Kemmling A; Marstrand J; Modrau B; Neeb L; Perez de la Ossa N; Puig J; Ringleb P; Roy P; Scheel E; Schonewille W; Serena J; Sunaert S; Villringer K; Wouters A; Thijs V; Ebinger M; Endres M; Fiebach JB; Lemmens R; Muir KW; Nighoghossian N; Pedraza S; Gerloff C;
    N Engl J Med; 2018 Aug; 379(7):611-622. PubMed ID: 29766770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial.
    Parsons MW; Yogendrakumar V; Churilov L; Garcia-Esperon C; Campbell BCV; Russell ML; Sharma G; Chen C; Lin L; Chew BL; Ng FC; Deepak A; Choi PMC; Kleinig TJ; Cordato DJ; Wu TY; Fink JN; Ma H; Phan TG; Markus HS; Molina CA; Tsai CH; Lee JT; Jeng JS; Strbian D; Meretoja A; Arenillas JF; Buck BH; Devlin MJ; Brown H; Butcher KS; O'Brien B; Sabet A; Wijeratne T; Bivard A; Grimley RS; Agarwal S; Munshi SK; Donnan GA; Davis SM; Miteff F; Spratt NJ; Levi CR;
    Lancet Neurol; 2024 Aug; 23(8):775-786. PubMed ID: 38880118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
    Wang Y; Li S; Pan Y; Li H; Parsons MW; Campbell BCV; Schwamm LH; Fisher M; Che F; Dai H; Li D; Li R; Wang J; Wang Y; Zhao X; Li Z; Zheng H; Xiong Y; Meng X;
    Lancet; 2023 Feb; 401(10377):645-654. PubMed ID: 36774935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).
    Rha JH; Shrivastava VP; Wang Y; Lee KE; Ahmed N; Bluhmki E; Hermansson K; Wahlgren N;
    Int J Stroke; 2014 Oct; 9 Suppl A100():93-101. PubMed ID: 22988894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.
    IST-3 collaborative group
    Lancet Neurol; 2015 May; 14(5):485-96. PubMed ID: 25819484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.
    Thomalla G; Boutitie F; Ma H; Koga M; Ringleb P; Schwamm LH; Wu O; Bendszus M; Bladin CF; Campbell BCV; Cheng B; Churilov L; Ebinger M; Endres M; Fiebach JB; Fukuda-Doi M; Inoue M; Kleinig TJ; Latour LL; Lemmens R; Levi CR; Leys D; Miwa K; Molina CA; Muir KW; Nighoghossian N; Parsons MW; Pedraza S; Schellinger PD; Schwab S; Simonsen CZ; Song SS; Thijs V; Toni D; Hsu CY; Wahlgren N; Yamamoto H; Yassi N; Yoshimura S; Warach S; Hacke W; Toyoda K; Donnan GA; Davis SM; Gerloff C;
    Lancet; 2020 Nov; 396(10262):1574-1584. PubMed ID: 33176180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteplase: new indication. Inadequately assessed in ischaemic stroke.
    Prescrire Int; 2004 Aug; 13(72):127-31. PubMed ID: 15532135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.
    Lang W; Stadler CH; Poljakovic Z; Fleet D;
    Int J Stroke; 2013 Feb; 8(2):95-104. PubMed ID: 23009193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances.
    Alper BS; Foster G; Thabane L; Rae-Grant A; Malone-Moses M; Manheimer E
    BMJ Evid Based Med; 2020 Oct; 25(5):168-171. PubMed ID: 32430395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
    Menon BK; Buck BH; Singh N; Deschaintre Y; Almekhlafi MA; Coutts SB; Thirunavukkarasu S; Khosravani H; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar J; Williams H; Field TS; Manosalva A; Siddiqui M; Zafar A; Imoukhuede O; Hunter G; Demchuk AM; Mishra S; Gioia LC; Jalini S; Cayer C; Phillips S; Elamin E; Shoamanesh A; Subramaniam S; Kate M; Jacquin G; Camden MC; Benali F; Alhabli I; Bala F; Horn M; Stotts G; Hill MD; Gladstone DJ; Poppe A; Sehgal A; Zhang Q; Lethebe BC; Doram C; Ademola A; Shamy M; Kenney C; Sajobi TT; Swartz RH;
    Lancet; 2022 Jul; 400(10347):161-169. PubMed ID: 35779553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
    Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.